This Week at FDA: Pregnancy exposure registries, PRV fee rates, and more

The Reagan-Udall Foundation for the FDA and FDA are also co-hosting a hybrid meeting on 16 October to discuss where the patient voice is needed in the rare disease product development timeline, its impact, and opportunities for patients to engage in the product development process.